ture will first deploy mySHOP 3.0 in a pilot stage covering Tiens
Group's four subsidiary stores, four direct-sales stores and 40 franchised
chain stores in China and expects the pilot stage to be operational by
December 2008. After the completion of an initial rollout, eFuture and
Tiens Group expect to further collaborate to complete a nationwide
expansion of the system to a further 96 subsidiary stores, 96 direct-sales
stores and 1,000 franchised chain stores in 2009.
In July 2006, Tiens Group selected eFuture's ONE POS-ERP R2003 Super
Market Management System for its Bannerstore Supermarket. Since its
selection, the R2003 Super Market Management system has been successfully
implemented in Bannerstore's headquarters back-office, six subsidiary
stores, 17 direct-sales stores and 23 franchised chain stores.
About Tiens Group Co., Ltd.
Founded in 1995 by Mr. Li Jinyuan, Tiens Group Co., Ltd. (Amex: TBV) is
a large-scale global enterprise with operations in over 190 countries and
regions and with a customer base of over 16 million worldwide. Since 1995,
Tiens Group has maintained continual, stable, and rapid growth. With an
anchor business in advanced biotechnology, particularly in the areas of
health food, health care, beauty care and home care products, Tiens Group
is also involved in financing, real estate development, education, cultural
exchanges, and modern logistics. Tiens Group is headquartered at the
Henderson Center in Beijing, China, and has production plants in the Wuqing
New Technology Development Zone of Tianjin, China.
Tiens Group is a direct selling company that is based on advanced
biotechnology devoted to developing health and wellness products and a
culture for a healthy lifestyle. Tiens Group operates
'/>"/>
SOURCE eFuture Information Technology Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 Related biology technology :1.
Access Pharmaceuticals Signs Merger Agreement to Acquire MacroChem Corp.2.
Senesco Signs a Supply Agreement for Polyplus-transfections Delivery System3.
Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis4.
Sigma-Aldrich Signs Agreement With Plextronics to Distribute Plexcore(R) Organic Electronics Materials5.
GlaxoSmithKline Signs Licensing Agreement With Compendia Bioscience6.
Medline Signs 3-Year Purchasing Agreement for Mouth Rinse From Chester Labs7.
Roche Signs Exclusive Distribution Deal with DxS for K-RAS and EGFR Cancer Mutation Tests8.
Digirad Corporation Signs Letter of Understanding With Johns Hopkins University School of Medicine9.
Cepheid Signs Group Purchasing Contract with Novation, the Nations Largest Healthcare Contracting Organization10.
Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations11.
NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics